Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine whether vitamin E would slow the progression of cognitive deterioration and dementia in aging persons with Down syndrome (DS). METHODS: A randomized, double-blind controlled clinical trial was conducted at 21 clinical sites, and researchers trained in research procedures recruited adults with DS older than 50 years to participate. Participants were randomly assigned to receive 1,000 IU of vitamin E orally twice daily for 3 years or identical placebo. The primary outcome was change on the Brief Praxis Test (BPT). Secondary outcomes included incident dementia and measures of clinical global change, cognition, function, and behavior. RESULTS: A total of 337 individuals were randomized, 168 to vitamin E and 169 to placebo. Both groups demonstrated deterioration on the BPT with no difference between drug and placebo. At baseline, 26% were diagnosed with dementia and there was an overall rate of incident dementia of 11%/year with no difference between groups. There was no effect on the secondary outcome measures. Though numerically higher in the treatment group, there was no difference in the number of adverse events (p = 0.079) and deaths (p = 0.086) between groups. CONCLUSIONS: Vitamin E did not slow the progression of cognitive deterioration in older individuals with DS. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that vitamin E does not significantly slow the progression of cognitive deterioration in aging persons with DS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · cited 1×
“Two clinical trials of individuals with AD demonstrated slower clinical progression and less functional deterioration over multiple years.(16,17) However, another trial in those with mild cognitive impairment demonstrated no benefit of vitamin E in slowing cognitive loss or reducing the transition to AD.”
BackgroundSelf-citationVitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 3×
“Assignment was stratified by site and by presence of AD.”
BackgroundSelf-citationOccurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159
Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro
Busciglio, J., & Yankner, B. A. (1995) · Nature · doi:10.1038/378776a0 · Cited by 741
Dysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., et al. (2014) · JAMA · doi:10.1001/jama.2013.282834 · Cited by 628
A Prospective Study of Alzheimer Disease in Down Syndrome
Lai, F., & Williams, R. S. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520440031017 · Cited by 561 · cited 1×
“Individuals with Down syndrome (DS) are uniquely vulnerable to Alzheimer disease (AD), with reports that those 35–40 years of age show key neuropathologic changes characteristic of AD and clinical signs of dementia around the age of 50 years.(4,5) With increasing life expectancy,(6) there is a growing need to identify…”
BackgroundSelf-citationGalasko, D. R., Peskind, E., Clark, C. M., Quinn, J. F., Ringman, J. M., Jicha, G. A., Cotman, C., Cottrell, B., Montine, T. J., Thomas, R. G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.85 · Cited by 377
Self-citationBruce, A. J., Malfroy, B., & Baudry, M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2312 · Cited by 216
Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation
Lott, I. T., Doran, E., Nguyen, V. Q., Tournay, A., Head, E., & Gillen, D. L. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.34114 · Cited by 136 · cited 12×
“Study conduct was done through a collaboration of international clinical research sites with research experience in adult individuals with DS.21 Recruitment occurred at 21 sites in 5 countries.”
ResultInfluential
Cited by
Alzheimer's disease in Down syndrome: an overlooked population for prevention trials
Strydom, A., Coppus, A., Blesa, R., Danek, A., Fortea, J., Hardy, J., Levin, J., Nuebling, G., Rebillat, A., Ritchie, C., et al. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.006 · Cited by 110
Further understanding the connection between Alzheimer's disease and Down syndrome
Snyder, H. M., Bain, L. J., Brickman, A. M., Carrillo, M. C., Esbensen, A. J., Espinosa, J. M., Fernandez, F., Fortea, J., Hartley, S. L., Head, E., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12112 · Cited by 105
Self-citationAntioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials
Rueda Revilla, N., & Martínez-Cué, C. (2020) · Antioxidants · doi:10.3390/antiox9080692 · Cited by 35
Metadata
- Authors
- Sano, M., Aisen, P. S., Andrews, H. F., Tsai, W.-Y., Lai, F., Dalton, A. J., For the International Down Syndrome and Alzheimer's Disease Consortium, International Down Syndrome and Alzheimer's Disease Consortium, McCallion, P., Zendell, A., Mintz, M., Young, J. M., Parmenter, T. R., Durvasua, S., Riches, V., Yazbeck, M., Shellard, N., Friedlander, R., Klancnik, J., Watt, K., Gratigny, S., Tsiouris, J., Patti, P., Prasher, V., Singh, B., Murphy, D., Lai, F., Beauchesne, M., Lawlor, B., McCarron, M., Rubin, L., Pomaro, N., Hernando, R. T., Crowell, T. A., Thorpe, L., Percy, M. E., Pasternak, S. H., Lovering, A. M., Stone, J., Kerins, G., Gruman, C., Heller, T., Hsieh, K., Macmillan, C., Batty, K. N., Capone, G., Lerner, A. J., & Hudson, L.
- Venue
- Neurology
- Published
- 2016-05-31
- Volume
- 86
- Issue
- 22
- Pages
- 2071-2076
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2347148793
- Cited by
- 61
- References
- 10
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial. https://app.cochat.ai/papers/10.1212/wnl.0000000000002714
- The paper
- Sano, M., Aisen, P. S., Andrews, H. F., Tsai, W.-Y., Lai, F., Dalton, A. J., For the International Down Syndrome and Alzheimer's Disease Consortium, International Down Syndrome and Alzheimer's Disease Consortium, McCallion, P., Zendell, A., Mintz, M., Young, J. M., Parmenter, T. R., Durvasua, S., Riches, V., Yazbeck, M., Shellard, N., Friedlander, R., Klancnik, J., . . . Hudson, L. (2016). Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial. Neurology. https://doi.org/10.1212/wnl.0000000000002714
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.